News
REGN
--
0.00%
--
Merck’s Lung Cancer Drug Is a Blockbuster. Other Companies Are Starting to Challenge Its Dominance.
A coming rival will be Regeneron, whose presentation showed that its immuno-oncology drug Libtayo reduced deaths in lung cancer patients by 43%, compared with chemo, during an 11-month treatment.
Barrons.com · 56m ago
National Institutes Of Health Expands Clinical Trials To Test Convalescent Plasma Against Coronavirus
-Reuters
Reuters · 5h ago
Late-breaking ESMO Presentation Shows Libtayo® (cemiplimab) Monotherapy Increases Overall Survival in First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of 50%
\- In the overall trial population, Libtayo reduced risk of death by 32% compared to chemotherapy
PR Newswire · 1d ago
Initial data from a pair of clinical trials may revive interest in arthritis drugs as COVID-19 treatments
There is some renewed hope for rheumatoid arthritis drugs like Eli Lilly’s Olumiant and Roche’s Actemra as possible COVID-19 treatments after a series of...
marketwatch.com · 1d ago
Sanofi, Regeneron’s Libtayo Delivers Positive Results In Pivotal Lung Cancer Trial
Sanofi (SNYNF) and Regeneron have announced positive pivotal trial data for the investigational use of PD-1 inhibitor Libtayo (cemiplimab) in first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.The trial
SmarterAnalyst · 1d ago
Sanofi, Regeneron Libtayo extends overall survival in first-line lung cancer
Sanofi (SNY) and Regeneron (REGN) presents positive trial data for the investigational use of PD-1 inhibitor Libtayo (cemiplimab) in first-line locally advanced or metastatic non-small cell lung cancer ((NSCLC)) at ESMO Virtual
Seekingalpha · 1d ago
Sanofi Announces Late-breaking ESMO Presentation Shows Libtayo Monotherapy Increases Overall Survival in First-line Advanced Non-small Cell Lung Cancer With Pd-l1 Expression of ≥50%
Positive pivotal trial data for the investigational use of PD-1 inhibitor Libtayo® (cemiplimab) in first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) were shared in a presentation at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
Benzinga · 1d ago
Sorrento Gets FDA Nod for Phase I Study on Coronavirus Antibody
Sorrento (SRNE) receives an FDA clearance to begin a phase I study on STI-1499 (COVI-GUARD) for treating hospitalized COVID-19 patients. Shares rise.
Zacks · 4d ago
Roche Reports Phase 3 Progress for Its Covid Pneumonia Treatment
Swiss drug giant Roche reported progress in the Phase 3 trial of a drug to treat coronavirus patients who have pneumonia.
TheStreet.com · 4d ago
Positive Pivotal Data for Libtayo® (cemiplimab) Monotherapy in Locally Advanced Basal Cell Carcinoma Featured as a Late-breaking Presentation at ESMO
Libtayo is the first investigational medicine to show a clinical benefit in advanced basal cell carcinoma following treatment with a hedgehog inhibitor in a prospective trial
PR Newswire · 4d ago
Sanofi/Regeneron Libtayo shows positive effect in skin cancer study
Sanofi (SNY) presents positive results from the Phase 2 trial for the PD-1 inhibitor Libtayo (cemiplimab), jointly developed by Regeneron (REGN), in patients with locally advanced basal cell carcinoma ((BCC)) who
Seekingalpha · 4d ago
Tracking William Nygren's Harris Associates Portfolio - Q2 2020 Update
Harris Associates 13F portfolio value increased from $36.11B to $41.11B this quarter.They increased Workday while reducing Regeneron Pharmaceuticals.The top three positions are Alphabet, Bank of America, and Charter Communications and they add up to ~16% of the portfolio.
Seekingalpha · 5d ago
Eli Lilly, Amgen Teaming Up On Covid-19 Treatments
Investor's Business Daily · 5d ago
Lilly and Amgen partner to manufacture potential coronavirus drugs
Eli Lilly has partnered with Amgen to increase the capacity of its experimental C-19 antibody treatment, a day after one of the drug was shown to reduce the need for hospitalization.
Reuters · 5d ago
Lilly and Pfizer Are Testing Treatments for Hospitalized Covid Patients
Lilly’s anti-inflammatory drug Olumiant reduced hospital stays when combined with Gilead’s remdesivir.
Barrons.com · 6d ago
Lilly's Coronavirus Antibody Treatment Found Effective, Safe In Mild-To-Moderate Patients
Eli Lilly And Co (NYSE: LLY) shares were moving higher Wednesday after the large-cap biopharma released positive proof-of-concept data for its LY-CoV555 monoclonal antibody treatment candidate for SARS-CoV-2, the virus that causes COVID-19.
Benzinga · 6d ago
Coronavirus update: Operation Warp Speed readies for vaccine as CDC tries to manage expectations
Operation Warp Speed is gearing up for widespread distribution of a potential vaccine, but top health officials tried to manage expectations for rapid deployment.
Yahoo Finance · 6d ago
Biotech Stock Roundup: GILD to Buy IMMU, SGEN Collaborates With Merck & More
The biotech sector remains in focus with regulatory and other pipeline updates.
Zacks · 6d ago
Top Biotech Stocks for Q4 2020
These are the biotech stocks with the best value, fastest growth, and most momentum for Q4 2020.
Investopedia · 09/15 20:41
Regeneron's Cocktail for Coronavirus Selected for RECOVERY Study
Regeneron's (REGN) investigational anti-viral antibody cocktail, REGN-COV2, has been selected for evaluation in the RECOVERY study.
Zacks · 09/15 15:06